Yes. We offer comprehensive target validation services for oncology programs, including gene knockdown or knockout studies, pathway validation, and phenotypic analysis in disease-relevant cancer cell lines. Our biology platforms support target-driven decision making in early drug discovery.

We provide customized cell-based assay development and screening services. With access to an extensive cell line library and multiple assay formats, we support functional evaluation, potency ranking, and selectivity assessment for small molecules and biologics.

Yes. We conduct kinase and enzyme panel screening to assess compound selectivity and off-target risk. Our biochemical assay platforms support flexible panel sizes, standardized data output, and fast turnaround to support lead optimization.

We offer in vivo pharmacology services using a variety of tumor models, including xenograft and syngeneic models. Study design, dosing strategy, and efficacy endpoints are customized based on project needs to support preclinical decision making.

Yes. Our DMPK services include PK profiling, bioavailability, clearance, and tissue distribution studies. We support multiple species and provide integrated data packages suitable for IND-enabling programs.

We support targeted protein degradation projects by providing cell-based degradation assays, mechanism-of-action studies, and pathway analysis. Our platforms are suitable for evaluating PROTAC and other TPD modalities.

Yes. We offer biological evaluation services for ADC programs, including target binding, internalization studies, cytotoxicity assays, and in vivo efficacy testing. Our workflow supports ADC discovery and early preclinical assessment.

We provide integrated drug discovery services covering target validation, assay development, screening, and preclinical efficacy studies. Flexible collaboration models and phased project execution are available to support biotech and pharmaceutical partners globally.